These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 21306925)

  • 21. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
    Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
    Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
    Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a.
    Slezak S; Jin P; Caruccio L; Ren J; Bennett M; Zia N; Adams S; Wang E; Ascensao J; Schechter G; Stroncek D
    J Transl Med; 2009 Jun; 7():39. PubMed ID: 19497108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia.
    Marchetti M; Tartari CJ; Russo L; Panova-Noeva M; Leuzzi A; Rambaldi A; Finazzi G; Woodhams B; Falanga A
    Am J Hematol; 2014 Jan; 89(1):68-73. PubMed ID: 24009132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.
    Landolfi R; Di Gennaro L; Falanga A
    Leukemia; 2008 Nov; 22(11):2020-8. PubMed ID: 18800144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The evaluation of the relevance of thrombin generation and procoagulant activity in thrombotic risk assessment in BCR-ABL-negative myeloproliferative neoplasm patients.
    Baccouche H; Ben Jemaa M; Chakroun A; Chadi S; Mahjoub S; Sfar I; Gorgi Y; Ben Romdhane N
    Int J Lab Hematol; 2017 Oct; 39(5):502-507. PubMed ID: 28497580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Women with unexplained recurrent pregnancy loss do not have evidence of an underlying prothrombotic state: experience with calibrated automated thrombography and rotational thromboelastometry.
    Bennett SA; Bagot CN; Appiah A; Johns J; Ross J; Roberts LN; Patel RK; Arya R
    Thromb Res; 2014 May; 133(5):892-9. PubMed ID: 24613698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Global coagulation in myeloproliferative neoplasms.
    Tripodi A; Chantarangkul V; Gianniello F; Clerici M; Lemma L; Padovan L; Gatti L; Mannucci PM; Peyvandi F
    Ann Hematol; 2013 Dec; 92(12):1633-9. PubMed ID: 23820940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?
    Maugeri N; Giordano G; Petrilli MP; Fraticelli V; de Gaetano G; Cerletti C; Storti S; Donati MB
    J Thromb Haemost; 2006 Dec; 4(12):2593-8. PubMed ID: 16959024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies.
    Robertson B; Urquhart C; Ford I; Townend J; Watson HG; Vickers MA; Greaves M
    J Thromb Haemost; 2007 Aug; 5(8):1679-85. PubMed ID: 17596137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of global coagulation assays in myeloproliferative neoplasm.
    Lim HY; Ng C; Rigano J; Tacey M; Donnan G; Nandurkar H; Ho P
    Blood Coagul Fibrinolysis; 2018 Apr; 29(3):300-306. PubMed ID: 29538005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Procoagulant activity of mononuclear cells is increased in myeloproliferative and myelodysplastic diseases.
    Bazzan M; Vaccarino A; Stella S; Foli C; Omedè P; Gallone G; Tamponi G; Pileri A
    Haemostasis; 1996; 26(3):157-63. PubMed ID: 8738590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Brain MRI-findings in Ph - negative myeloproliferative disorders].
    Tanashyan MM; Melikyan AL; Kuznetsova PI; Raskurazhev AA; Shabalina AA; Konovalov RN
    Ter Arkh; 2019 Jul; 91(7):29-34. PubMed ID: 32598733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Large external quality assessment survey on thrombin generation with CAT: further evidence for the usefulness of normalisation with an external reference plasma.
    Perrin J; Depasse F; Lecompte T; ; ;
    Thromb Res; 2015 Jul; 136(1):125-30. PubMed ID: 25563679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The defective stimulus-response coupling for oxidative reactions in neutrophils from patients with polycythemia vera.
    Samuelsson J; Palmblad J
    Acta Haematol; 1996; 96(4):264-5. PubMed ID: 8922499
    [No Abstract]   [Full Text] [Related]  

  • 37. Thromboelastometry changes in myeloproliferative neoplasms-surrogate for a procoagulant haemostatic imbalance or a consequence of technical reasons? : Comment on A. Tripodi et al. Ann Hematol (2013) 92:1633-1639.
    Nagler M; Ten Cate H
    Ann Hematol; 2014 Oct; 93(10):1781-2. PubMed ID: 25163411
    [No Abstract]   [Full Text] [Related]  

  • 38. Polymorphonuclear neutrophils from JAK2(V617F) positive MPD patients do not support hypercoagulability: A study with calibrated automated thrombography (CAT).
    Perrin J; Ranta D; Empereur F; Vigneron C; Feugier P; Lecompte T
    Blood Cells Mol Dis; 2011 Mar; 46(3):235-8. PubMed ID: 21306925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera.
    Panova-Noeva M; Marchetti M; Spronk HM; Russo L; Diani E; Finazzi G; Salmoiraghi S; Rambaldi A; Barbui T; Ten Cate H; Falanga A
    Am J Hematol; 2011 Apr; 86(4):337-42. PubMed ID: 21442635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.
    Panova-Noeva M; Marchetti M; Russo L; Tartari CJ; Leuzzi A; Finazzi G; Rambaldi A; ten Cate H; Falanga A
    Thromb Res; 2013 Jul; 132(1):88-93. PubMed ID: 23735588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.